Zydelig

FDA
Pharma

FDA halts single-arm nods for PI3K blood cancer meds

Before the adcomm, the FDA has already dissuaded Incyte from filing its PI3K inhibitor parsaclisib in certain lymphomas based on single-arm data.
Angus Liu Apr 20, 2022 9:57am
FDA

FDA probes TG Therapeutics' Ukoniq for potential death risks

Feb 7, 2022 9:53am
Gilead Sign

Gilead pulls 2 accelerated approvals in lymphoma

Jan 24, 2022 11:29am
Bayer

Bayer's Aliqopa leaps ahead of Gilead's Zydelig in lymphoma

Apr 10, 2021 8:30am
up arrow sales growth chart

Can Epizyme's Tazverik launch top Gilead's Zydelig?

Feb 25, 2020 11:17am
fda

Verastem wins FDA nod for AbbVie-ditched cancer drug Copiktra

Sep 25, 2018 11:41am